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Abstract
In this thesis, we develop statistical methods for studying tumour growth and metastatic lymph node
spread in breast cancer. The methods can be used for analysing breast cancer disease progression before
diagnosis. They may be used to answer questions such as: For how long does a tumour grow inside
of the body before it is detected? How much will the tumour metastasise in the lymph nodes before
detection? Or, which women have a high risk of missing breast cancer at mammography screening?
These questions are important for studying the effects of mammography screening at an individual level.
We work in a framework called continuous growth models. This is an alternative to Markov models,
which is the most commonly used approach for modelling breast cancer disease progression. Standard
Markov models assume that all women in each disease state are identical, making the model easy
to implement and practically useful. Unfortunately, women with breast cancer are not identical, and
relaxing this assumption quickly increases the Markov model’s complexity. Continuous growth models
are instead more complex at the outset. However, as the number of clinical factors increase, continuous
growth models become more flexible and less complex than Markov models.
In Study I, we focus on a continuous growth process used for modelling tumour volume at diagnosis.
We provide a detailed description of the so called Stable Disease Assumptions that are used for continuous
growth modelling. We use them to derive new theoretical results for the model. These are then integrated
into our growth model, which helps to simplify and reduce computational complexity of the model.
With these results, we were able to greatly reduce the computational time needed for estimating growth
parameters. The theoretical results derived in Study I are further used in Studies II and III.
In Study II, we extend our continuous growth model to also include a sub-model for metastatic
lymph node spread. The result is a joint model of tumour volume and number of lymph node metastases
at diagnosis, conditional on mammography screening history and mammographic density. When applied
on empirical data on 1860 incident invasive breast cancer cases, our model provides a dramatically better
fit than other models in current use. Furthermore, we show that our sub-model of lymph node spread
can be estimated independently of the tumour growth process. This property forms the first part of the
theoretical basis for study IV. In Study II, we use the property to validate our lymph node spread model
on an independent data set, consisting of 3961 women diagnosed with invasive breast cancer.
In Study III, we show how to study the effect of other clinical factors on metastatic lymph node
spread. Our approach is to regress clinical factors on the proportionality constant in our model for
lymph node spread. We illustrate our method by studying the association between hormone replacement
therapy (HRT) and tumour growth rate and rate of lymph node spread. Using data from 1631 women
diagnosed with breast cancer, we estimate that women using HRT have a 36% lower rate of lymph node
spread than non-users (95% confidence interval: 58% to 8%). This can be contrasted with the effect of
HRT on tumour growth rate. We estimate growth rates to be 15% slower in HRT users (p = 0.16). We
also derive theoretical distributions for metastatic lymph node spread at future points in time. We use
them to illustrate the potential consequences of false negative screens, in terms of lymph node spread.
In Study IV, we use the method developed in Study III to study the association between clinical
factors and rate of breast cancer lymph node spread. We use data on 10950 women to study the
associations with grade, estrogen receptor (ER) status, progesteron receptor (PR) status, molecular
subtype, and a polygenic risk score. We found that grade 2 and 3 tumours, respectively, were associated
with 1.63 and 2.17 times faster rates of lymph node spread than grade 1 tumours (p < 10−16). ER
negative breast cancer was associated with a 1.25 times faster spread than ER positive and PR negative
breast cancer was associated with a 1.19 times faster spread than PR positive cancer (p = 0.0011, p
= 0.0012, respectively). Her2-enriched breast cancer was associated with a 1.53 times faster spread
than luminal A cancer (p = 0.00072).
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Chapter 1
From general to personalised screening
Breast cancer is the most common form of cancer among women in the world. It has been
estimated that approximately 600 000 women die from breast cancer each year globally (1).
In Sweden, around 7500 women are diagnosed every year, out of which 1 400 die due to
breast cancer (2). In most cases, breast cancer death is caused by metastases that have spread
to other parts of the body, effectively shutting down vital body functions. If breast cancer is
found and treated before it has spread, it is more likely to be curable. Therefore, in order to
reduce mortality from breast cancer, most western countries have implemented nationwide
breast cancer screening programs. Today, approximately half of all diagnosed breast cancers
are detected by routine mammography screening.
The first breast cancer screening program in Europe was introduced in a selection of regions
of Sweden in 1986 (3). It was based on age, which is the most important breast cancer risk
factor in women. The program invited women age 50 to 69 to mammography screening every
two years. In the same year, the Stockholm County Council decided to extend the program to
include women aged 40 to 74 (4). Today, the Swedish national guidelines (5) are to invite all
women age 40 to 74 to mammography screening every 18 to 24 months. Exact practices vary
based on age and county. Still today, the general screening recommendations are mainly age
based.
The Swedish guidelines on mammography screening (6) were primarily based on the results
from the Swedish Two-County Screening Trial (7), that was conducted between 1977 and 1984.
Since the 1980s, there has been great progress in our general understanding of cancer (8; 9),
and a large number of discoveries concerning breast cancer biology and risk factors have been
made. Researchers have discovered rare genetic mutations that lead to a highly increased risk
of breast cancer (10; 11), as well as more than 300 common genetic variants that modestly
increase risk (12). Hormone replacement therapy, oral contraceptives, and alcohol intake have
been found to be associated with increased risk of breast cancer (13; 14; 15), whilst having
children, breast feeding them, and staying physically active have been found to be associated
with decreasing risk (16; 17; 18). Furthermore, each woman has different risk depending on
her breast tissue composition, BMI, age of first menarche, and age of menopause (19; 20; 21).
Thanks to our improved understanding of breast cancer biology, there have been major
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breakthroughs in breast cancer treatment. Today breast cancer is subclassified based on biomark-
ers, such as tumour grade, Ki-67 proliferation marker, estrogen receptor status, progesteron
receptor status, and human epidermal growth factor receptor 2 (HER2) status. Breast cancer
prognosis differs across subtype, and each subtype responds differently to different treatments.
This discovery has lead to the development of less generalised and more personalised treat-
ment, in the form of targeted therapies. One of the more successful examples is trastuzumab,
an antibody used for treating HER2-enriched breast cancer. This type of cancer is prone to early
metastasis, but since the discovery of trastuzumab, its prognosis has been much improved.
With treatment becoming personalised, and with so many breast cancer risk factors having
been discovered, this begs the question: shouldn’t breast cancer screening also be personalised?
Before personalised screening can reach practice, it first needs clinical evidence. The gold
standard for testing medical hypotheses is randomised clinical trials. However, these are highly
resource intensive and expensive to perform. Further, of all possible personalised screening
programs, it is unclear which one would be considered optimal. For practical and ethical reasons,
a large number of potential screening programs cannot be tested in clinical trials; there is not
enough women, and many would receive sub-optimal screening patterns. To use resources
effectively, and to reduce harm and suffering, a personalised screening program should be
well designed before it is tested. An alternative approach could be to design and scrutinise
potential personalised screening programs with the help of computer simulations. A large
number of alternative screening programs could be assessed, and the one considered optimal
could be tested in a randomised clinical trial employing real human subjects. To create such
a simulation program, the natural development of breast cancer could be estimated from a
number of different sources, such as clinical trials, expert opinion, and observational screening
data. Unfortunately, creating a realistic simulation program is conceptually very difficult, and
requires advanced statistical methods (22).
Statistical modelling of breast cancer progression is most commonly done using multi-state
Markov models (23). These models assume that breast cancer progresses through a number of
pre-specified and homogeneous disease states, and that these same states are shared among
all breast cancer patients. For example, the basic model for breast cancer progression assumes
three states: no detectable cancer, preclinical cancer detectable by screening, and clinical symp-
tomatic breast cancer (24). This model has been extended to include, for example, states for
metastatic lymph node spread (25; 26), and more complex models have been suggested (27).
Homogeneous disease states are practical, but they are ultimately a simplification of reality. As
I will illustrate in the following sections, the success of screening depends on a large number
of biological and technical factors. Many of these are likely interdependent. In order to design
personalised screening programs, flexible models are needed that allow for many clinical fac-
tors being accounted for. Increasing the number of disease states and clinical factors quickly
increases the Markov model’s complexity, which makes the model unsuitable for designing
individualised screening programs. A recent alternative is continuous growth models. Unlike
multi-state models, they aim to capture the underlying continuous process of tumour progres-
sion. Continuous growth models are more complex than Markov models at the outset, but as
1. From general to personalised screening 3
the number of clinical factors increase, continuous growth models become more flexible and
less complex than Markov models. Additionally, continuous growth models can more easily
incorporate interdependencies between biological processes. This makes them more suitable
for designing individualised screening programs, motivating further research on the topic.
Chapter 2
Aims and structure
My overarching aim is to develop continuous growth models that can be used for studying breast
cancer disease progression, based on observational breast cancer screening data. I also want
illustrate how the models can be applied to patient data to draw clinically relevant conclusions.
The specific aims of each study are:
I. To simplify existing continuous growth models by clarifying their underlying assumptions
and by developing new theory.
II. To use the theory developed in Study I to develop joint models of breast cancer tumour
growth and metastatic lymph node spread.
III. To show how to model associations between clinical factors and rate of metastatic lymph
node spread, and to derive new probability distributions for the number of lymph node
metastases at earlier and later points in time.
IV. To use the models from Studies II and III to investigate associations between clinically
relevant factors and rate of metastatic lymph node spread.
Studies I - III are highly technical, and require in-depth knowledge of statistics to read.
Therefore, prior to and up to the point where the articles are presented, my aim with this thesis
is to give the reader a technical context, rather than a detailed technical description that very
few readers would benefit from. I will mainly focus on discussing technical factors that need to
be taken into consideration for designing individualised screening programs. Before presenting
articles I - IV, I give the following context:
• First, I describe what it means to assess a screening program, and show examples of how
it has been done for breast cancer.
• Second, I discuss and try to intuitively explain the major technical and statistical factors
contributing to screening effectiveness.
• Third, I introduce natural history models from the literature, i.e. Markov models, con-
tinuous growth models, and CISNET models. From this chapter onwards, more detailed
statistical knowledge is required.
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• Finally, I give a short summary of my papers, and end with a discussion of possible future
directions for the research of my thesis.
Chapter 3
How can a breast cancer screening
program be assessed?
To assess the effectiveness of breast cancer screening, one has to study its potential costs, harms,
and benefits, and weigh them against one another. When considering all the available evidence
for and against screening, if the benefits outweighs the costs and harms, then one can say
that breast cancer screening is effective. This has been done by several independent research
groups. The conclusions vary. The scientific community generally agrees that there are benefits
to mammography screening, in the form of prolonged survival for women attending screening.
The main point of contention is how big the benefits are in relation to the harms and costs (28).
In this section, I will give an overview of how to estimate the survival benefits of screening,
based on clinical trials and simulation studies.
In medicine, mortality and survival is studied by collecting data from human subjects over
time, recording their times of study entry and death, together with other important medical
information. After adjusting for age at entry, and relevant medical factors, one can use this
type of data to estimate how long patients live. If this is done for two groups of patients, one
being a control group and one receiving mammography screening, then one can study whether
screening improves survival.
Survival data has mainly been collected from randomised clinical trials and observational
studies. In the first case, data is collected prospectively as part of a randomised controlled
experiment. In the latter, medical data is collected retrospectively from women taking part in the
normal healthcare system. Both types of data have been used to assess screening. Unfortunately,
four severe biases occur when assessing screening based on observational data (29): lead time
bias, length bias, overdiagnosis, and self selection bias. These biases occur when survival is
measured from time of diagnosis, when comparing breast cancer survival between screen
detected cases and symptomatically detected cases (cases found in-between screening rounds
or outside of the screening program). For this reason, survival studies based on observational
data are considered much less reliable than those based on randomised clinical trials.
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Clinical trials
An independent UK panel on breast cancer screening (30) identified 11 completed randomised
clinical trials, involving 650 000 women, carried out in Europe and North America between
1963 and 1991. The trials measured overall survival from time of study entry; they compared
women who were invited to screening for breast cancer to women who were not invited. Based
on these trials, the panel estimated a 20% reduction in breast cancer mortality after 13 years
of follow-up in women invited for screening. They noted that the relative reduction in mor-
tality will be higher for women actually attending screening. The systematic review by the
Cochrane collaboration (28; 31) critisised a number of the trials for employing sub-optimal
randomisation procedures. Based on the three studies that were appropriately randomised,
they estimated a 10% reduction in mortality.
Screening trials trials can also give rise to biased mortality ratios when women in the non-
screening group receive mammography screens at other hospitals. This bias will not, however,
make screening seem more effective, but rather less effective.
Simulation studies
Recognising that there are limitations and flaws in the randomised trials used to evaluate
the effects of screening on cancer mortality, there have been various efforts to estimate screen-
ing effects based on simulation studies. These can be designed with the help of expert opinion,
and can incorporate data from observational screening studies and clinical trials. One of the
larger initiatives to assess the effects of screening is the CISNET (Cancer Intervention and
Surveillance Modelling Network) consortium.
The CISNET consortium was established in 2000 by the U.S. National Cancer Institute
and currently consists of six research groups from Georgetown University, Dana-Farber Cancer
Institute, Stanford University, University of Wisconsin, Erasmus MC, and University of Texas
MDACC (22). These groups develop simulation-based modelling approaches for investigating
the impact of breast cancer interventions, with a focus on prevention, screening, and treat-
ment. Each group has developed models for breast cancer progression, including submodels
for incidence, natural history, and survival/treatment. The models have been calibrated against
incidence and mortality data from the Surveillance, Epidemiology and End Results (SEER)
Program for U.S. women aged at least 25 in 1975.
Comparing breast cancer mortality in 1990 to that in 2000, the CISNET group estimated
that breast cancer mortality had decreased by 24%. Each group has concluded that mammog-
raphy screening has contributed to this decrease. Their assessment of the relative contribution
from screening have however differed, ranging from 28% to 65% of the total decrease. In 2018 ,
CISNET evaluated the contributions of screening and treatment for different molecular subtypes
of breast cancer (32). The subtypes were defined based on the tumours estrogen receptor (ER)
status and human epidermal growth factor receptor 2 (HER2) status. The group estimated that
in 2012, compared to baseline mortality rates, total reduction in mortality rate from interven-
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tions was 49%, ranging from 37% for ER-/HER2- breast cancer to 58% for ER+/HER2+ breast
cancer. The contributions of screening and treatment were estimated to differ substantially
between molecular subtypes. Screening was estimated to have contributed to 31% of the total
mortality reduction for ER-/HER2- and to 48% of the reduction for ER+/HER2+ breast cancer.
Chapter 4
Factors contributing to screening
effectiveness
Individualised screening programs will need to be well designed before they can be tried out
in a clinical setting. A program is more likely to have the intended effectiveness if it is designed
based on realistic models of breast cancer disease progression. By realistic, I mean in the sense
of capturing mechanisms and factors that are likely to contribute to screening effectiveness. In
this section, I will discuss and try to give an intuitive description of the technical and statistical
factors that contribute to screening effectiveness. The factors are not presented in any strict
logical ordering, so the first factor should not be interpreted as the most important one, and
the last factor should not be interpreted as the least important.
Screening effectiveness
The effectiveness of a screening program is very dependent on how effectiveness is defined.
In other words, screening effectiveness depends on how one weighs the costs and harms of
screening with the benefits of screening. Weighing the risks and benefits usually involves a
trade-off between competing objectives. For example: maximizing quality of life versus maxi-
mizing life expectancy versus minimizing the resources required for screening implementation
(33). Screening effectiveness can alternatively be be defined in terms of cost-effectiveness.
New medical interventions, such as drugs, medical equipment, and new procedures, are
often evaluated by health authorities/policy-makers in so called cost-effectiveness studies. The
aim of such studies is to assess the intervention by estimating all of its future expected costs,
health benefits, and risks, and then to quantify them, calculate their present value, and finally to
estimate the cost-effectiveness. A positive cost-effectiveness can be interpreted as the monetary
amount (dollars) that must be spent in order to gain an additional (quality adjusted) life-year.
A small positive value means that small monetary resources need to be spent per life-year saved,
and a large value means that large monetary resources are required for a small life gain. The
cost-effectiveness ratio is defined as
CER=
Cp
Up
, (4.1)
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where Up is the present value of future health utilities gained (quantities of health risks and
benefits) and Cp is the present value of future intervention costs. Costs and health utilities may
be taken from literature reviews or analyses of register data. Cost-effectiveness can be estimated
from a health sector perspective, or from a societal perspective. In many cases, interventions
are compared to an already existing treatment alternative. In those cases, the incremental
cost-effectiveness ratio is used instead. An intervention, or an intervention compared to an
alternative, can be said to be cost effective if the cost-effectiveness ratio, or incremental cost-
effectiveness ratio, meets a certain threshold. In practice, many health authorities use a ’soft’ or
informal threshold. In the UK, this threshold is 20 to 30 thousand pound sterling per life-year
saved (34), and in Sweden it is 700 000 to 1 220 000 kronor SEK per life-year saved (35). If the
cost for each life-year saved is much higher than these numbers, the intervention is generally
not accepted.
Cost-effectiveness studies are carried out by health authorities in many countries, but are
still considered controversial. One of the ethical concerns is fairness. If cost-effectiveness deter-
mines treatment options, people who are ill may be left without treatment. Another concern is
connected to the choice of which costs to count, and how to count them. One of the benefits
of cost-effectiveness analysis is that it can expose costs, make them explicit, and in doing so
improve transparancy in policy making decisions (36).
For the remainder of this chapter I will use the word screening effectiveness to mean the
cost-effectiveness of a screening program.
Costs, harms, and benefits
Screening effectiveness depends how the costs, harms, and benefits of screening are counted
and measured. The direct costs of screening are the medical costs for equipment, personnel, and
maintaining the hospital. The indirect costs may include costs from job time lost, and lost tax
revenue. Generally, the cost can be measured economically, e.g. as a monetary (dollar) amount
C . Apart from economic costs, the harms of screening may be: overtreatment of slow-growing
or in-situ tumours, increased anxiety, and use of ionising radiation (30). If these harms are
measured in medical or health economic studies, they may be quantified as life-years lost from
screening, or as quality-adjusted life-years lost from screening. In the same way, the benefits of
screening can be quantified as life-years gained from screening, or quality-adjusted life-years
gained from screening. If health utility is chosen as the quantity for harm, then one also has
to define what a quality-adjusted life-year means, and measure it using a health economic
instrument, such as EQ-5D (37).
Costs, harms, and benefits can be weighed differently over time, so that those that occur
close to the present time have higher value, and those that occur far in the future are given a
lower value. Mathematically, this is usually done by discounting future quantities into present
valued quantities with a time-increasing discount factor. To clarify, if the expected cost t years
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into the future is Ct , then the present value of that cost Ct p can be defined as
Ct p =
Ct
λt
, (4.2)
where λ ≥ 1 is a discount factor (e.g. λ = 1.03). Similarly, the total present cost Cp can be
defined as the discounted sum of all future costs, from 0 to year T
Cp =
T∑
t=0
Ct p =
T∑
t=0
Ct
λt
. (4.3)
Breast cancer risk
Breast cancer risk is, perhaps, the most apparent factor that can contribute to screening ef-
fectiveness. I present here a simplified argument of why that is so. Assume that there are two
women, A and B, and that the women are identical in every possible way, except that woman
A has, at every point in time, an x > 1 times higher risk of breast cancer. Assume further that
the additional costs for screening the two women is CS and that the expected health (or health
utility) gained from treating them earlier when they have cancer is U . If both women are
screened once, the cost-effectiveness ratio of each screening visit is
CER=
CS
pqU
, (4.4)
where p > 0 is each woman’s probability of having breast cancer, and q is the average probability
of finding the cancer when it is present. At this visit, woman A has a higher probability of having
breast cancer than woman B, because of her higher risk. If the costs CS are positive, then, as
long as the net expected health benefit U is positive, equation (4.4) is a decreasing function in
p. A small cost-effectiveness ratio means an effective intervention, so it follows explicitly that
it is more cost-effective to screen woman A than woman B.
This argument does not hold if the woman has a higher risk from a factor that also impacts
costs or health benefits. For example, a predictive risk factor that also predicts life expectancy,
such as alcohol use (15; 38), affect the health benefit from the shorter life-span of heavy alcohol
drinkers. Similarly, older women who are at a higher risk of breast cancer because of their age
might not live long enough to see the benefits of screening and treatment. Even though it does
not hold strictly for arbitrary risk factors, the argument is clear for factors that are believed to
primarily affect breast cancer risk.
Life expectancy in the absence of breast cancer
Life expectancy plays an important role in screening effectiveness. In terms of life-years saved,
a woman who is expected to die naturally, from other causes, shortly after a breast cancer di-
agnosis, will benefit less from breast cancer treatment. As mentioned above, this fact becomes
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important when studying breast cancer risk factors that also shorten women’s remaining life
spans, such as alcohol use and and age. If such breast cancer risk factors are incorporated into
simulation programs used in evaluating screening effectiveness, it is crucial that the shortened
life-span is also accounted for.
The importance of life expectancy can be argued for using cost-effectiveness directly. As-
sume now that two almost identical women A and B have the same breast cancer risk r, and the
same costs of screening CS , but that woman A has a longer life-span. The expected gain in utility
for treating woman A, UA, is higher than the expected gain in utility for treating woman B, UB.
If the probability for each woman having breast cancer is p and the probability of detection is
q, then the cost-effectiveness ratio for screening woman A is
CERA =
CS
pqUA
, (4.5)
and the the cost-effectiveness ratio for screening woman A is
CERB =
CS
pqUB
. (4.6)
As long as the utilities for treating women A and B are positive, it holds that
CERA =
CS
pqUA
<
CS
pqUB
= CERB, (4.7)
which means that it is more cost-effective to screen woman A than woman B.
Breast cancer treatment
For screening to be effective, treatment must either be less resource intensive or/and more
effective at earlier stages of breast cancer progression. If neither is true, then screening cannot
be effective.
At one extreme, if there is no effective treatment, or if treatment is too expensive or other-
wise unavailable, then finding the tumours through screening will not help reduce mortality. At
another extreme, if treatment can fully cure breast cancer at late stages of disease progression,
then screening for the cancer will be unnecessary. It should be noted, however, that better treat-
ment does not necessarily decrease screening effectiveness. As long as the treatment works
better at earlier stages of breast cancer progression, then screening will have a positive impact
on survival, and can still be effective.
Today, treatment of invasive breast cancer depends on the characteristics of the tumour,
including the tumour’s grade, Ki-67 proliferation marker, estrogen receptor status, progesteron
receptor status, and human epidermal growth factor receptor 2 status. New treatment options
have been discovered that are well suited for treating certain subtypes of breast cancer, such
as trastuzumab for treating HER2-enriched breast cancer. The breast cancer screening trials
(30) provided evidence that early treatment improves breast cancer survival. For the newer
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treatment options that came after the screening trials, the effect of early treatment on survival
has not been established.
Screening method
The choice of screening method influences screening effectiveness through the test’s costs,
specificity, and sensitivity. Increased costs make the screening method less cost-effective, low
specificity adds costs for additional medical examinations and dis-utilities for overtreatment,
and a high sensitivity of course increases screening effectiveness by identifying more breast
cancer patients.
The standard screening method used today is mammography, a test in which low doses
of X-rays are used to examine the breasts. The sensitivity of a mammography screening test
depends heavily on the woman’s breast tissue composition. The female breast has two main
tissue types: fatty tissue, that appears dark on a mammogram; and fibroglandular tissue, that
has a bright appearance. Tumours also appear bright on mammograms, and can easily be
concealed in fibroglandular tissue. Mammographic density, measured as a function of the pixel
intensities in the image, reflects the different tissues in the breast, and is also an important risk
factor for breast cancer (19).
Mammography screening sensitivity is one of the major topics in the articles of my thesis.
In article I, we sought to understand how mammographic density and tumour volume interact
in their effect on screening sensitivity.
Disease progression
The last important factor that I am going to mention is the rate of breast cancer disease pro-
gression, which is the main focus of the articles of my thesis.
Virchow (39) hypothesised in 1862 that tumours develop from a single cell. Today, this
hypothesis has been shown to be true for the majority of cancers, including breast cancer
(40). Breast cancer normally develops in the lobules or ducts of the breast from cells that have
mutated. As tumour cells divide, they mutate and get a number of distinct features (9): they
resist cell death, get unlimited replicative potential, maintain proliferation, and start evading
growth suppressors. As tumours grow, they may start forming their own blood vessels and
invade neighbouring tissue. Breast cancer that is not yet invasive is called breast cancer in situ.
This type of breast cancer respects tissue boundaries and is localised to the lobules (lobular
carcinoma in situ) or ducts (ductal carcinoma in situ). Generally, these do not spread quickly;
the prognosis is good for breast cancer in situ. Invasive breast cancer, on the other hand, will
start spreading if left untreated, and may metastasise in the lymph nodes close to the breast,
or in other parts of the body.
The purpose of screening is to find breast cancer at early stages of disease progression, when
curability is high. A woman who attends screening can get a breast cancer diagnosis either
as a result of a screening visit or as a result of breast cancer symptoms occurring in-between
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two screening round. If a tumour progresses at a very aggressive rate, then the chance for
symptomatic tumour detection increases. If a tumour is symptomatically detected in-between
screening rounds, then, by definition, the woman who had the tumour was not helped by
screening. Consequently, screening effectiveness for an individual woman must depend on how
quickly the tumour progresses through its different stages.
Breast cancer progresses on a number of different scales simultaneously. For example, the
cancer progresses in terms of the tumour becoming more mutated, larger, more vascularised,
and invading more neighboring tissue. Two simplistic yet important scales for understand-
ing screening effectiveness are symptomatic progression and metastatic progression. In terms
of symptomatic progression, breast cancer is non-symptomatic at onset, but starts displaying
symptoms as the tumour grows. The early breast cancer Markov models modelled symptomatic
progression: the cancer progressed from being non-symptomatic and not detectable by screen-
ing, into non-symptomatic but detectable by screening, and finally became symptomatic breast
cancer (24). In terms of metastatic progression, most breast cancers progress from a localised
breast cancer stage, into a regional stage with metastatic lymph node spread, and finally into a
distant metastatic stage, with breast cancer metastases in the brain, lungs, liver, or bone marrow.
Prognosis is worse for later stages of breast cancer progression.
Some of the most important factors that shed light on the rate of disease progression are:
tumour size, lymph node metastases, distant metastases, and molecular subtype. Tumour size
is informative of the tumours growth rate. Additionally, tumours are more likely to metastasise
at larger sizes, and also become more easily detectable at mammography screening. Lymph
node metastases commonly occur before distant metastatic spread, and influence long term
prognostis when present at diagnosis (41; 42). Distant metastases cause breast cancer death,
and lymph node metastases can be informative of micro metastases in distant regions of the
body. Finally, different breast cancer molecular subtypes have different breast cancer prognoses,
and likely progress at different rates.
In the next chapter, I will discuss different ways in which breast cancer progression have
been modelled in the statistical literature. The discussion will focus on models of invasive breast
cancer. For a description of models of in situ breast cancer, used by CISNET, see van Ravesteyn
et al. (43).
Chapter 5
Natural history models
The aim of my thesis is to develop statistical models of breast cancer disease progression. As
I described in the previous section, two of the key components for understanding the natural
history of breast cancer are tumour growth and metastatic lymph node spread. In this chapter,
I will discuss existing modelling approaches from the literature, focusing on Markov models
and continuous growth models. I will also briefly describe the CISNET models.
This chapter is a bit more technical than the previous chapters. Readers without knowledge
of statistics may get less benefit from reading it.
Markov models
The Multi-state Markov model has a long history in the analysis of screening data. The basic
model for breast cancer assumes three states: no detectable cancer, preclinical cancer detectable
by screening, and clinical symptomatic breast cancer (24). Several extensions of the model have
been described in the literature; for example Chen et al. (25; 26) propose a five-state model
that enriches the preclinical and clinical states by splitting both states into two sub-states, one
with positive nodal involvement and one with negative nodal involvement. Parameter estimates
of these models have been obtained with several different methods: Duffy fit the 3-state model
based on the likelihood of prevalent breast cancer screening cases and interval cases (split
into two groups by arrival times), Chen et al (44) fit the 3- and 5-state models based on the
likelihood of prevalent and subsequent screens from screening trials, Taghipour et al. (45) fit
the 3-state model (with an additional state added for deaths due to other causes) to screening
cohort data, and Weedon-Fekjaer et al. (46) fit the 3-state model based on the likelihood of
prevalent screening cases and interval cases after the prevalent screen.
Many applications of these models have been published in recent years, for example, for
evaluating overdiagnosis (47; 48) and lead time bias when comparing screen detected cancers
and cancers found outside of screening programs (27). For a relatively recent review of multi-
state Markov models see Uhry et al.(23).
Markov models assume homogeneous disease states. While this is practical, it is a simplifi-
cation of reality. For example, screening sensitivity is usually assumed to be constant during the
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preclinical state. Homogeneous disease states also imply that we can not add risk factors to the
model without increasing the complexity of the model significantly. Since we want to model
breast cancer progression and take risk factors into consideration at the same time, alternative
models are needed to improve our understanding of disease progression with respect to the
screening procedure.
Continuous models applied to non-screened populations
An alternative approach to Markov models is to model tumour progression with a continu-
ous growth function, and add other processes on top of the growth function. Bartoszynski et
al. (49) proposed several growth functions, such as Gompertz growth, logistic growth, and
exponential growth. In the exponential case, they proposed that tumour volume at time t could
follow the function
V (t, r) = V0e
t/r , t ≥ 0, (5.1)
where r is an individually assigned growth rate and V0 = 1000 µm3 is the starting volume of the
tumour. Furthermore, they allowed the inverse growth rate r to follow a gamma distribution
with shape parameter τ1 and inverse scale parameter τ2,
fR(r) =
τ
τ1
2
Γ (τ1)
rτ1−1e−τ2r , r ≥ 0. (5.2)
On top of the growth function, they assumed that eventually, the tumour would be detected
spontaneously from its symptoms. In their model, the probability for instantaneous symptomatic
detection at time Tdet = t after tumour initiation depended linearly on the tumour volume
P(Tdet ∈ [t, t + d t)|Tdet ≥ t,R= r) = ηV (t, r)d t +O(d t), V (t, r)≥ V0. (5.3)
Plevritis et al. (50) described a similar model with exponential growth, gamma distributed
inverse growth rate, and a hazard for symptomatic detection proportional to tumour volume.
The model differed in the choice of starting volume for the tumour. Instead of V0 = 1000 µm3,
they assumed that the tumour started from an observable volume corresponding to a sphere
of diameter d0 = 2mm. Early analyses using models (5.1) - (5.3) were based on data from
women diagnosed with breast cancer in non-screened populations (50; 51) and therefore based
inference on the density for tumour volume at symptomatic detection, which was shown by
Plevritis et al. (50) to be
fVdet (v) = ητ1
τ
τ1
2
(τ2 +η(v − V0))τ1+1 , v > V0. (5.4)
This density was derived from the density for tumour volume at symptomatic detection condi-
tioned on the inverse growth rate
fVdet |R=r(v) = ηrexp(−ηr(v − V0)), v > V0 (5.5)
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and the joint density for tumour volume at symptomatic detection and the inverse growth rate
fVdet ,R(v, r) = η
τ
τ1
2
Γ (τ1)
r(τ1+1)−1exp(−r(τ2 +η(v − V0))), v > V0, r ≥ 0. (5.6)
Continuous models applied to populations under screening
Weedon-Fekjaer et al.(52; 53) described a continuous growth model that obtained estimates
of growth and screening parameters based on screening data. They based tumour growth on a
logistic function proposed by Spratt et al. (54), which assumes that the tumour starts at size
Vcel l , corresponding to a cell, and grows to size Vmax corresponding to a spherical tumour of
diameter dmax = 128 mm (40 tumour doublings). The volume V (t) at time t was described by
V (t) =
Vmax
1+
  Vmax
Vcel l
1/c − 1e−κt/cc , (5.7)
where κ is a log-normally distributed random effect with log-mean α1 and log-variance α2
fκ(x) =
1
x
p
2piα2
e−
(log x−α1)2
2α2 , x > 0. (5.8)
Spratt et al. found the constant c = 4 to give the best model fit. The same constant was used
by Weedon-Fekjaer et al.
In order to model screening data, Weedon-Fekjaer et al. (52; 53) modelled screening sensi-
tivity as function of tumour diameter d,
S(d) =
ea1+a2d
1+ ea1+a2d
, (5.9)
where a1 and a2 are screening parameters.
In the first of these studies, Weedon-Fekjaer et al. (52) estimated α1,α2, a1 and a2 by
combining two likelihoods: one based on the distribution of tumour sizes at the first screening,
and one based on the incidence of interval cases. In the second of these studies, Weedon-
Fekjaer et al. (53) extended the model by incorporating previous negative screening tests into
the likelihood. This was achieved by calculating the distribution of tumour size conditioned on
time since the last negative screen.
Abrahamsson and Humphreys (55) described an approach that extends the model of Bar-
toszynski et al. to screening data, and further build on the ideas presented by Weedon-Fekjaer
et al. They modelled tumour progression using (5.1) - (5.3), assuming an initial diameter
d0 = 0.5 mm, and modelled screening sensitivity as a function of both tumour size (d) and
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mammographic density (m)
S(d,m) =
eα1+α2d+α3m+α4d·m
1+ eα1+α2d+α3m+α4d·m . (5.10)
They estimated τ1,τ2,η,α1,α2,α3 and α4 from a sample of incident cases of breast cancer by
maximising the product of two likelihoods: one based on the distribution of tumour sizes at
screen detection, and one based on the distribution of tumour sizes at symptomatic detection,
both conditional on the screening history of the woman (the time and number of previous
screens). Because pathologists tend to round tumour diameters to the nearest mm, they express
the likelihood function in terms of the probabilities for tumours to be in one of the 24 millimetre
size intervals [0.5,1.5), [1.5,2.5), [2.5,7.5), [7.5,12.5), ..., [67.5,72.5), [72.5,85), [85,95),
..., [145, 155). They expressed the likelihood as
L(0|θ ) = n!
Πioi!
∏
i
poii , (5.11)
where n is the number of cases, oi is the number of cases in size interval i, pi is the probability for
a tumour to be in size interval i at deteection, and θ is a vector of the unknown parameters. In
order to describe how pi is calculated in the two cases, the authors introduced a very convenient
notation:
Ai - The tumour is in size interval i at symptomatic detection.
B j - The tumour is detected at screening number j (at time point t j).
Ci,t - The tumour is in size interval i at time point t.
Dt, f - In the absence of a screening programme, a tumour will be symptomatically de-
tected at time point t + f , f ≥ 0.
Bcj - The tumour is not detected at screenings 1 to j, j ≥ 1.
For a woman with screening time t1, t2, ..., tK , they showed that in the screen detected case,
pi could be calculated as
pi∝ P(BK |Ci,tk)P(Ci,tk)
∑
s−1≤i
P(BcK−1|Ci,tk ∩ Cs−1,tk−1)P(Cs−1,tk−1 |Ci,tk),K ≥ 1, (5.12)
pi∝ P(BK |Ci,tk)P(Ci,tk),K = 1. (5.13)
To calculate the probability for the previous missed screens, they followed the trajectory
of a tumour passing through the midpoints of size intervals i and s at time points tk and tk−1,
and used the formula
P(BcK−1|Ci,tk ∩ Cs,tk−1) = (1− P(ds−1 ,m) · (1− P(ds−2 ,m) · ... · (1− P(ds−K ,m),
where ds−1 , ..., ds−K are the projected tumour diameters at the previous screens.
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In their model, P(Cs−1,tk−1 |Ci,tk) was calculated by finding appropriate inverse growrth rates
for tumour passing through intervals i and s−1 (at both boundary values of the size interval
s−1, using the midpoint of interval i) and then using the distribution function for the growth
rate conditioned on the tumour being at least in interval i at symptomatic detection. We note,
however that this potentially leads to a small bias—the tumour being in size interval i at time
point tk is not equivalent to the tumour being in size interval i, or an interval representing a
larger size, at symptomatic detection.
Finally, to calculate P(Ci,tk), (the probability density function for tumour size of an unde-
tected breast cancer case) the authors modified a procedure suggested by Weedon-Fekjaer et al.
(53). They calculated the quantity via back-calculation, tracking tumours backwards in time
from their hypothetical symptomatic detection, i.e. from the tumours expected outcome, had
the woman not attended screening. In practice, they performed the numerical calculation
P(Ci,tk)∝
∑
0≤ f
∑
i≤g
P(Ci,tk |Dtk , f ∩ Ag) · P(Ag). (5.14)
In order to do this they first derived the density for growth rate conditioned on volume at
symptomatic detection, shown under (5.1) - (5.3) to be
fR|Vdet=v(r) =
(τ2 +η(v − V0))
Γ (τ1 + 1)
 
r(τ2 +η(v − V0))
(τ1+1)−1exp(−r(τ2 +η(v − V0))), r ≥ 0.
(5.15)
From this large model, the authors were able to retrieve parameter estimates for the average
growth rate of tumours, the time to symptomatic detection, and the effect of tumour diameter
and mammographic density on screening sensitivity.
In a later study, Abrahamsson et al. (56) extended their framework to estimate the effects
of BMI on tumour growth rate, and the effect of breast size on time to symptomatic detection.
These effect were estimated by regressing the log expected value of the inverse growth rate on
BMI (b)
log E[R] = α+ β b, (5.16)
and by regressing on breast size (s) using the log of the effect parameter (η) in (5.3)
log η= γ+δs. (5.17)
We used a related approach to incorporate covariates into models of lymph node spread in
Studies III and IV.
Models of metastatic lymph node spread
In the context of continuous growth models, models of metastatic lymph node spread have
been proposed by Plevritis et al. (50), Hanin and Yakovlev (51), Shwartz (57), and the CISNET
university of Wisconsin group. To model breast tumour spread, the Wisconsin group used the
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model proposed by Shwartz (57), which assumes that tumour volume V grows exponentially
with an individually assigned growth rate, and that the rate of additional lymph node spread
is equal to λ= b1 + b2V + b3V ′. The group has modified the growth component of the model
slightly. Instead of exponential tumour growth, they assumed an exponential Gompertz func-
tion with decelerating doubling time. In fitting the model to observed breast cancer incidence
data, the group found the overall model fit to be inadequate, but subsequently introduced ad-
ditional, somewhat ad-hoc, assumptions to improve model fit. Firstly, when simulating lymph
node progression, they found that the Shwartz model produced too much lymph node spread
for large tumours. Consequently, they simulated lymph node spread using an adjusted diameter
(reducing the tumour diameter by 25%) in the spread model. At the other end of the spectrum,
they assumed that 1% of all invasive tumours had four affected lymph nodes at tumour onset
and that 2% had 5 or more affected lymph nodes (in their model, 5 or more affected lymph
nodes involved was considered to be synonymous with distant metastatic spread).
Hanin and Yakovlev’s model (51) was also based on the model of Shwartz, and assumed
that the tumours grow exponentially and that the rate of lymph node spread is proportional
only to tumour volume. They introduced a number of additional assumptions and provided a
detailed mathematical description of the model. Plevritis et al. described a simpler model in
which the hazard of a localised tumour spreading to the lymph nodes is proportional to the
volume of the tumour. They also relied on exponential tumour growth.
From the fact that: a) the Wisconsin group had to introduce additional assumptions to
fit the Shwartz model to data and b) that the Shwartz model represents a more general case
of Hanin and Yakovlev as well as Plevritis et al., it is likely that the mentioned models can
be improved. This claim can be further backed up by noting two problems in the models of
Shwartz, and Hanin and Yakovlev (see Figure 1).
The first problem is that under the Shwartz model, a slow growing tumour will have, on
average, more node spread compared to a fast growing tumour, given that the two tumours are
of the same size. This property is not supported by empirical evidence. Slow growing tumour
having comparatively higher degree of lymph node spread implies that screen detected cancers
would have more lymph node involvement compared to interval cancers, due to length biased
sampling. Empirical data shows that this is not true (58). The model of Hanin and Yakovlev is
also affected by this problem.
The model of Hanin and Yakovlev exhibits a second problem: namely, that the rate of
additional lymph node spread grows excessively with increasing tumour volumes. In their
model, the expected number of lymph nodes for tumours of diameters 20 mm is approximately
1000 times larger compared to the expected number of lymph nodes in tumours of diameter
2 mm. Such an extreme difference is not supported by clinical data. It is not uncommon to
find tumour of less than 2 mm with one or several lymph nodes affected. Moreover, even,
large tumours do not exhibit spread with lymph nodes affected in the thousands. Shwartz
(57) found that, when simulating cohorts of symptomatic cancers based on his model, too
few affected lymph nodes in tumours with diameters smaller than 1 mm were produced. The
CISNET Wisconsin group found similar patterns of behaviour in their modified approach. They
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also found that their model generated too many lymph nodes in large tumours. Even though
this named second problem, strictly speaking, does not have to apply to the Shwartz model, the
findings of Shwartz and the CISNET Wisconsin group do indeed indicate that the problem will
apply to to the Shwartz model. Together, these problems indicate that new models of lymph
node spread are needed.
For a detailed mathematical description of the problems I mentioned above, see article II
in this thesis.
CISNET models
To investigate the impact of breast cancer interventions, including prevention, screening, and
treatment, the CISNET consortium have developed six different breast cancer progression
models. Each model can be divided into components, such as incidence, natural history, and
survival/treatment. The CISNET groups use the following types of natural history models:
• The Georgetown University group uses a Markov model with cancer types: ductal carci-
noma in situ, local invasive breast cancer, locally spread breast cancer, and breast cancer
with distant metastases. They also include pre-clinical states with age-dependent expo-
nentially distributed sojourn times.
• The Dana-Farber Cancer Institute group uses a three-state Markov model with an asymp-
tomatic and clinically undetectable breast cancer state, an asymptomatic but clinically
detectable state, and a diagnosed breast cancer state. At diagnosis, the stage of the breast
cancer is drawn from a stage distribution based on observed incident breast cancer cases.
• The Stanford University group uses a continuous growth model with exponential tu-
mour growth, with inverse growth rate drawn from a gamma distribution, a hazard of
symptomatic clinical detection proportional to current tumour size, and specifies hazard
functions for the tumour to spread (similar to those described in Plevritis et al. (50)).
• The University of Wisconsin group uses a continuous growth model with Gompertz
growth, growth rate drawn from a lognormal distribution, symptomatic detection follow-
ing a failure-time model, and lymph node spread following an inhomogenous Poisson
process (57).
• The The Erasmus MC group uses the MISCAN breast cancer model (59), in which tumours
are assumed to have a fatal diameter, drawn from a weibull distribution.
• The University of Texas MDACC group uses a population based approach where they
simulated incident cohorts of breast cancer cases with appropriate tumour characteristics.
These models are calibrated against incidence and mortality data from the Surveillance, Epi-
demiology and End Results (SEER) Program for U.S. women aged at least 25 in 1975.
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Figure 5.1: To illustrate problems 1 and 2, described previously, I have plotted the lymph node models
of Shwartz (solid) and Hanin and Yakovlev (dotted) based on hypothetical parameter values. To the left:
doubling time vs. expected number of affected lymph nodes at tumour diameter 12 mm. To the right:
tumour diameter vs. expected number of affected lymph nodes for a tumour growing with a doubling
time of 178 days.
Chapter 6
Summary of studies
Data sources
The analyses presented in this thesis use data from three studies, here abbreviated as CAHRES,
ST01-08, and Libro-1. The inclusion-exclusion criteria that were used varied across the differ-
ent analyses. I therefore only provide a brief summary of the studies/data used. For complete
details on the different studies, see articles I-IV.
CAHRES (Cancer and hormone replacement study) is a case control study, consisting of
all Swedish born women between the ages of 50 and 74, that were diagnosed with invasive
breast cancer in Sweden from October 1993 to March 1995. The study had a participation rate
of 84% (n=3345), and patients were matched to randomly selected controls from the general
population based on the expected age frequency distribution of the cases. For the purpose of
our analyses we use only the cases. In an extension of the CAHRES study, analog mammo-
graphic images were retrieved from mammography screening units and radiology departments
managing mammography screening in Sweden. Information on tumour size, degree of lymph
node spread, screening history, mode of detection, grade, ER status, and PR status was collected
from the Swedish Cancer Registry and the Stockholm-Gotland Breast Cancer Registry. The col-
lection of this data has been described previously by Rosenberg et al. (60; 61) and Eriksson et
al. (62). In another extension of the CAHRES, DNA samples were collected from a subgroup of
the full study population (63). 1500 women were randomly selected, together with all women
who had taken hormone replacement therapy (191 cases) and all women with self-reported
diabetes (110 cases). These women were contacted by mail and those who consented were
given blood sampling kits to be used at their primary health care facility. From all deceased
breast cancer cases, attempts were made to retrieve archived tissue samples. Blood samples
were collected from 1322 cases and archived tissue was collected for 247 cases (85% of all
selected). DNA was isolated from 3 ml of whole blood and from non-malignant cells in the
paraffin-embedded tissue samples. DNA samples were genotyped on a custom Illumina iSelect
Array (iCOGS) (64).
ST01-08 consists of all women diagnosed with invasive breast cancer in Stockholm from
2001 to 2008. Women were identified through the Stockholm-Gotland Regional Breast cancer
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quality register, and information was collected on tumour size, lymph node involvement, grade,
ER status, and PR status (65).
Libro-1 has the same study base as ST01-08. All women in the Stockholm-Gotland Regional
Breast Cancer quality register, still alive in 2009, diagnosed with invasive breast cancer between
between 2001 and 2008, and younger than age 80 at diagnosis were invited to participate in
Libro-1. Invitations were mailed out in 2009, and 62% (n = 5715) of the invited women
consented to take part in the study. These women gave blood specimens for genetic analysis,
and were asked to provide web questionnaire information. Of these, 5125 were successfully
genotyped in a large-scale genotyping study on breast cancer risk (66). 5122 patients had
enough remaining DNA for mutation testing using targeted sequencing. For the women in the
Libro-1 study, data on molecular markers were retrieved from medical and pathology records
at treating hospitals. From these, molecular subtypes were assigned based on each woman’s
age at diagnosis and ER, PR, HER2, and Ki67 status, using a random forest algorithm (67).
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Study I
Title:
Modelling breast cancer tumour growth for a stable disease population
Background & aims:
Continuous growth models offer a promising framework in which to study the role of indi-
vidual risk factors on breast cancer progression. However, the underlying assumptions of the
model have not been formalised to the same degree as other frameworks have. New formalism
could open the door to many new development in the field. We therefore set out to explicitly
formulate the underlying assumptions of the model, and to use these to develop new theory. A
specific aim was to develop analytical formulas that could be used to simplify the likelihood
described in Abrahamsson and Humphreys. In addition, we wanted to correct the small error
in the calculation of P(Cs−1,tk−1 |Ci,tk), and improve the computational complexity when back-
calculating P(Ci,t); see Chapter 5.
Theoretical results:
We firstly specified three assumptions, which we call stable disease population assumptions.
These are that:
A1. the rate of births in the population is constant across calendar time.
A2. the distribution of age at tumour onset is constant across calendar time.
A3. the distribution of time to symptomatic detection is constant across calendar time.
As long as A1 and A2 hold, there is a constant incidence rate, which was stated as an assumption
in both Weedon-Fekjaer et al. (53) and Abrahamsson and Humphreys (55).
We next showed that if we think of each individual as belonging to any one of three states
at any particular point in time,
PBe f ore - disease free state (prior to breast cancer tumour onset),
PTumour - breast cancer state (as of yet undetected),
PAf ter - post symptomatic detection state.
and if each individual progress though these three states only once, and if assumptions A1 - A3
hold, then, in the absence of screening and competing events, the following two results follow:
1. The probability for an individual to have an undetected tumour at a particular/current
time point is proportional to the time it will spend in tumour growth (i.e. in state PTumour).
2. For an individual with a currently undetected tumour at time point s, the probability density
that tumour onset occurred exactly t ′ years earlier is 1/t, given that t is the eventual time it
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will spend in PTumour
With the help of these assumptions, assuming tumour progression following models (5.1) -
(5.3), we derived analytical expressions for:
• the probability density function for sizes of undetected tumours,
• the probability density function for growth rate conditioned on tumour size, and
• the probability density function for size at symptomatic detection conditioned on current
(undetected) tumour size.
These results were used for simplifying the calculation of the likelihood for screen detected
tumour size conditioned on previous screening history; see equations (5.12) and (5.13). We
achieved this by exchanging equation (5.14) with the analytical density for size of undetected
tumours. This simplification made it possible to vectorise the likelihood calculation. Using the
density for growth rate conditioned on tumour size, we were also able to correct the small
error in the calculation of P(Cs−1,tk−1 |Ci,tk).
Empirical results:
We used the new likelihood to estimate inverse growth rates, individual variation in inverse
growth rates, time to symptomatic detection, and screening sensitivity parameters based on a
sample of 1901 cases from the CAHRES study. These cases had data on tumour diameter, mode
of detection, numbers and times of previous screening visits, and a measure of mammographic
density (percent density, PD). After coding the new estimation procedure in R, we reduced the
computational time by 88% (for obtaining point estimates, using the same starting values).
In our study, screening test sensitivity was modelled in two ways. We modelled screening
test sensitivity using a logistic function, which depended on tumour diameter d (in mm), PD
m (scaled to [0,1]) and an interaction term expressed as the ratio of PD to tumour diameter
squared m/d2:
exp(β1 + β2d + β3m+ β4m/d2)
1+ exp(β1 + β2d + β3m+ β4m/d2)
, (6.1)
where β1, β2, β3, and β4 are model parameters. The interaction term was included to capture
an interplay between tumour size and area mammographic percent density. We compared this
to a model where β4 was set to zero. The addition of the interaction term to the sensitivity
model significantly improved model fit (p=0.013, using a likelihood ratio test). This was the
first time a screening sensitivity model of this complexity has been fitted to this type of data.
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Study II
Title:
Joint models of tumour size and lymph node spread for incident breast cancer cases in the
presence of screening
Background & aims:
Breast cancer tumour growth and metastatic lymph node spread are dependent processes. As
a tumour grows in size, the probability for lymph node spread increases. In Chapter 5, we
described two problems present in models of metastatic lymph node spread from the literature.
These are that: (a) the existing models imply that slow growing tumours have a higher degree
of lymph node spread, compared to fast growing tumours, and (b) the models imply either an
unrealistically high degree of lymph node spread for large tumours or an unrealistically low
degree of spread for small tumours. We wanted to create a joint process of tumour growth
and metastatic lymph node spread where these two problems were not present, and use these
processes to jointly model tumour size and number of lymph node metastases at diagnosis for
incident breast cancer cases in the presence of screening.
Theoretical results:
Assuming that tumour progression following models (5.1) - (5.3), we derived three new pro-
cesses for metastatic lymph node spread. All three were based on inhomogeneous Poisson
processes.
In the first model, the Poisson process had an intensity that was proportional to the first
derivative, with respect to time, of tumour volume. In the second model, the Poisson process had
an intensity that was proportional to the number of times the tumour cells have divided, to the
power k, and the rate of cell division in the tumour. In the third model, the Poisson process had
an intensity that was proportional to the same quantities as the second process. However, this
process differed in that it was possible for different individuals to have different proportionality
constants. The proportionality constant was assumed to follow a gamma distribution.
With the help of the theory derived in Study I and assuming a logistic model for screen-
ing test sensitivity, we derived the joint likelihood of tumour size and number of lymph node
metastases, given a patients screening history, mode of detection, and mammographic density,
based on the three different processes. The likelihood was shown to be separable into a lymph
node component and a tumour size component. This was a key result for studies III and IV.
Empirical results:
Using data on tumour diameter and number lymph node metastases from a sample of 1860
women from CAHRES, complete with screening history and mammographic density measure-
ments, we found that the best model fit was achieved for the third model, when k = 4. We
validated this model of lymph node spread on a sample of 3961 cases from ST01-08. The final
model did not exhibit problems (a) or (b).
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Study III
Title:
Random effects models of lymph node metastases in breast cancer: quantifying the roles of
covariates and screening using a continuous growth model
Background & aims:
The number of lymph node metastases present at diagnosis depends on the rate of lymph
node spread and the tumour volume, which in turn depends on the rate of tumour growth.
We wanted to show how the effect of clinical factors on both tumour growth rate and rate
of lymph node spread could be estimated. For this purpose, we chose to estimate the effect
of postmenopausal hormone replacement therapy (HRT), which has been shown to increase
breast cancer incidence. As a secondary objective, we wanted to estimate the effect of a false
negative mammography screening test on number of lymph node metastases.
Theoretical results:
This study had three theoretical results. We first showed how to estimate the effect of clinical
factors on the rate of lymph node spread by regressing the clinical factor on the log of the
proportionality constant in our Poisson process for breast cancer lymph node spread. Secondly,
we derived an analytical expression for the probability of having N f lymph nodes affected at a
future time point t f , conditional on tumour volume at diagnosis V , number of lymph nodes
affected at diagnosis N , and screening history H. Thirdly, we derived the probability of having
Ne lymph nodes affected at a previous time point te, conditional on tumour volume at diagnosis
V , number of lymph nodes affected at diagnosis N , and screening history H. In both of our
approaches, screening history H denotes the number and times of previous screening visits and
whether the tumour was symptomatically or screening detected.
Empirical results:
Using data on number of lymph node metastases, tumour diameter, and HRT use from 1631
women diagnosed with invasive breast cancer from CAHRES, we estimated that women using
HRT have a 36% lower rate of lymph node spread than non-users. The 95% confidence interval
ranged from a reduction of 58% to a reduction of 8%. Of the 1631 women used for estimating
the association between HRT use and rate of lymph node spread, 1373 women had complete
data on screening history and mammographic density. Based on these we estimated that tu-
mour in women taking HRT, on average, grow at a 15% reduced growth rate, compared to
tumours in women not taking HRT. However, at α= 0.05, this was not statistically significant
(p = 0.16).
We also illustrated the potential consequences of false negative screens by plotting the
probability for lymph node positivity at later time points for women who were lymph node
negative at screening detection, and by plotting the probability for lymph node negativity at
earlier time points for women who were lymph node positive at symptomatic detection.
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Study IV
Title:
Lymph node metastases in breast cancer: investigating associations with tumour characteristics,
molecular subtypes, and polygenic risk score using a continuous growth model
Background & aims:
Women who are diagnosed with breast cancer, within the Swedish health care system, are
given treatment partly based on measurements of tumour grade, estrogen receptor (ER) sta-
tus, progesteron receptor (PR) status, and human epidermal growth factor receptor 2 (HER2)
status. These factors, together with each woman’s age and Ki67 status can be used to estimate
a tumour’s molecular subtype (67).
The purpose of our study was to investigate association between rate of breast cancer lymph
node spread and grade, estrogen receptor status, progesteron receptor status, a decision tree
derived PAM50 molecular subtype, and a polygenic risk score.
Empirical results:
Using data on a total of 10950 women from CAHRES and ST01-08, we modelled the rate of
metastatic breast cancer lymph node spread as a function of clinical factors.
We modelled the association between lymph node spread and grade in two different ways.
Modelling the association on a continuous scale, we estimated the rate ratio, associated with
a unit increase in grade, to be 1.51 (95% confidence interval: 1.34, 1.69). The corresponding
p-value was smaller than 10−16. Modelling the association between grade and lymph node
spread on a discrete scale, using grade 1 as reference, the rate ratio and 95% confidence interval
for grade 2 tumours was 1.59 (1.20,2.06). The corresponding estimate for grade 3 tumours
was 2.32 (1.73,2.99). The p-value for this model was smaller than 10−16.
Compared to ER negative breast cancer, ER positive breast cancer was associated with a rate
ratio and corresponding 95% confidence interval of 0.61 (0.47,0.76). The estimated p-value
was 1.1 · 10−4. Similarly for PR positive breast cancer, the rate ratio and corresponding 95%
confidence interval was estimated as 0.65 (0.52, 0.78). The p-value was estimated as 1.2 ·10−4.
In the analysis of molecular subtypes, HER2-enriched breast cancer was associated with a
rate ratio and corresponding 95% confidence interval of 1.83 (1.05, 4.18), compared to luminal
A breast cancer. The p-value for association between molecular subtype and rate of lymph node
spread, based on a likelihood ratio test with 3 degrees of freedom, was 7.2 · 10−4.
We did not find any convincing evidence that the polygenic risk score is associated with
the rate of lymph node spread.
Chapter 7
Future directions
In the breast cancer literature, the effectiveness of screening has mainly been investigated based
on randomised clinical trials and simulation studies. Randomised clinical trials are expensive
and resource intensive, but have the potential to give clear cut and reliable results. Statistical
models, on the other hand, are cheap and reusable once developed. Furthermore, simulation
programs can be developed using data from a number of different sources, such as clinical
trials, expert opinion, and observational screening data. Unfortunately, because of complex
interactions between the biological processes leading to breast cancer death, realistic models
are very hard to develop. A complete model of breast cancer needs to incorporate sub-models
for treatment, disease onset, disease progression, and screening.
The aims of my thesis have been to develop statistical models of breast cancer disease
progression and screening, based on observational breast cancer screening data, and to apply
these models to patient data in order to draw clinically relevant conclusions. In this thesis,
we have been able to develop new statistical theory for continuous growth models, and new
models of metastatic breast cancer lymph node spread. We have also shown how these models
can be used in practice to study the interaction between clinical factors and tumour progression.
A natural next step for these models would be to incorporate them into a larger framework
that also models disease onset, distant metastatic spread, or breast cancer treatment/survival.
Related directions that I am interested in pursuing are: to translate the models of breast
cancer tumour growth and metastatic lymph node spread into analogous models of melanoma
tumour growth and metastatic lymph node spread, and to develop continuous models of the
natural history of liver cancer caused by hepatitis virus. In the second case, exponential tumour
growth could be analogous to exponential proliferation of the virus, and symptomatic debut
could correspond to onset of liver cancer. In some countries, testing for hepatitis infection is
part of general health care practice for injecting drug users, in a similar way that mammography
screening is common practice for women.
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